

# David K Chang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4703848/publications.pdf>

Version: 2024-02-01

82  
papers

15,193  
citations

66343

42  
h-index

60623

81  
g-index

86  
all docs

86  
docs citations

86  
times ranked

20786  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Genomic analyses identify molecular subtypes of pancreatic cancer. <i>Nature</i> , 2016, 531, 47-52.  | 27.8 | 2,700     |
| 2  | Whole genomes redefine the mutational landscape of pancreatic cancer. <i>Nature</i> , 2015, 518, 495-501.   | 27.8 | 2,132     |
| 3  | Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. <i>Nature</i> , 2012, 491, 399-405.  | 27.8 | 1,741     |
| 4  | Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , 2017, 32, 185-203.e13.  | 16.8 | 1,428     |
| 5  | Whole-genome landscape of pancreatic neuroendocrine tumours. <i>Nature</i> , 2017, 543, 65-71.  | 27.8 | 716       |
| 6  | CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , 2016, 29, 832-845.   | 16.8 | 645       |
| 7  | Molecular subtypes of pancreatic cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 207-220.   | 17.8 | 573       |
| 8  | Interrogating open issues in cancer precision medicine with patient-derived xenografts. <i>Nature Reviews Cancer</i> , 2017, 17, 254-268.   | 28.4 | 527       |
| 9  | The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. <i>Nature</i> , 2012, 486, 266-270.   | 27.8 | 297       |
| 10 | Margin Clearance and Outcome in Resected Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2855-2862.  | 1.6  | 296       |
| 11 | The prognostic and predictive value of serum CA19.9 in pancreatic cancer. <i>Annals of Oncology</i> , 2012, 23, 1713-1722.  | 1.2  | 240       |
| 12 | Targeting the <sc>LOX</sc> / <sc>hypoxia</sc> axis reverses many of the features that make pancreatic cancer deadly: inhibition of <sc>LOX</sc> abrogates metastasis and enhances drug efficacy. <i>EMBO Molecular Medicine</i> , 2015, 7, 1063-1076. | 6.9  | 223       |
| 13 | Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. <i>Clinical Cancer Research</i> , 2015, 21, 2029-2037.  | 7.0  | 209       |
| 14 | <i>Sleeping Beauty</i> mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 5934-5941.                            | 7.1  | 201       |
| 15 | Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. <i>International Journal of Cancer</i> , 2014, 135, 1110-1118.   | 5.1  | 192       |
| 16 | Hypermutation In Pancreatic Cancer. <i>Gastroenterology</i> , 2017, 152, 68-74.e2.  | 1.3  | 174       |
| 17 | The histone deacetylase SIRT2 stabilizes Myc oncoproteins. <i>Cell Death and Differentiation</i> , 2013, 20, 503-514.   | 11.2 | 171       |
| 18 | Histomolecular Phenotypes and Outcome in Adenocarcinoma of the Ampulla of Vater. <i>Journal of Clinical Oncology</i> , 2013, 31, 1348-1356.   | 1.6  | 142       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development. <i>Clinical Cancer Research</i> , 2017, 23, 1638-1646.                      | 7.0  | 136       |
| 20 | Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. <i>Scientific Reports</i> , 2016, 6, 35848.                                   | 3.3  | 127       |
| 21 | Targeting mTOR dependency in pancreatic cancer. <i>Gut</i> , 2014, 63, 1481-1489.  | 12.1 | 107       |
| 22 | Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. <i>Cell Reports</i> , 2016, 14, 907-919.                           | 6.4  | 107       |
| 23 | Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. <i>Gut</i> , 2018, 67, 2142-2155.                        | 12.1 | 100       |
| 24 | Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. <i>Cancer Cell</i> , 2020, 38, 198-211.e8.                                    | 16.8 | 99        |
| 25 | Clinical and molecular characterization of HER2 amplified-pancreatic cancer. <i>Genome Medicine</i> , 2013, 5, 78.   | 8.2  | 97        |
| 26 | Neuropilin-2 Promotes Extravasation and Metastasis by Interacting with Endothelial $\alpha 5$ Integrin. <i>Cancer Research</i> , 2013, 73, 4579-4590.                    | 0.9  | 97        |
| 27 | Synoptic reporting improves histopathological assessment of pancreatic resection specimens. <i>Pathology</i> , 2009, 41, 161-167.  | 0.6  | 94        |
| 28 | Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. <i>Gastroenterology</i> , 2021, 160, 362-377.e13.   | 1.3  | 90        |
| 29 | PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance. <i>Genes and Development</i> , 2016, 30, 2669-2683.                              | 5.9  | 88        |
| 30 | Expression of S100A2 Calcium-Binding Protein Predicts Response to Pancreatectomy for Pancreatic Cancer. <i>Gastroenterology</i> , 2009, 137, 558-568.e11.                | 1.3  | 82        |
| 31 | HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. <i>Cell Reports</i> , 2020, 31, 107625.   | 6.4  | 78        |
| 32 | Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. <i>Oncogene</i> , 2010, 29, 5957-5968.                                     | 5.9  | 76        |
| 33 | Somatic Point Mutation Calling in Low Cellularity Tumors. <i>PLoS ONE</i> , 2013, 8, e74380.   | 2.5  | 67        |
| 34 | Adjuvant chemotherapy in elderly patients with pancreatic cancer. <i>British Journal of Cancer</i> , 2014, 110, 313-319.   | 6.4  | 64        |
| 35 | Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 2617-2631.   | 1.6  | 63        |
| 36 | BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. <i>British Journal of Cancer</i> , 2017, 116, 1021-1026. | 6.4  | 61        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | Recruitment and Activation of Pancreatic Stellate Cells from the Bone Marrow in Pancreatic Cancer: A Model of Tumor-Host Interaction. <i>PLoS ONE</i> , 2011, 6, e26088.  | 2.5  | 55        |
| 38 | Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. <i>Nature Genetics</i> , 2017, 49, 825-833.   | 21.4 | 55        |
| 39 | Clinical and immunohistochemical features of 34 solid pseudopapillary tumors of the pancreas. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 267-274.  | 2.8  | 53        |
| 40 | Clinical and pathologic features of familial pancreatic cancer. <i>Cancer</i> , 2014, 120, 3669-3675.   | 4.1  | 53        |
| 41 | Pancreatic cancer genomics. <i>Current Opinion in Genetics and Development</i> , 2014, 24, 74-81.   | 3.3  | 50        |
| 42 | Precision Oncology in Surgery. <i>Annals of Surgery</i> , 2020, 272, 366-376.   | 4.2  | 48        |
| 43 | Mining the genomes of exceptional responders. <i>Nature Reviews Cancer</i> , 2014, 14, 291-292.   | 28.4 | 38        |
| 44 | Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. <i>Oncotarget</i> , 2015, 6, 44551-44562.  | 1.8  | 37        |
| 45 | Molecular Subtyping and Precision Medicine for Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 149.  | 2.4  | 34        |
| 46 | Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. <i>Chinese Clinical Oncology</i> , 2019, 8, 16-16.  | 1.2  | 33        |
| 47 | Understanding pancreatic cancer genomes. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2013, 20, 549-556.  | 2.6  | 31        |
| 48 | Improving outcomes for operable pancreatic cancer: Is access to safer surgery the problem?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1036-1045.  | 2.8  | 29        |
| 49 | Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 2671-2685.  | 3.8  | 29        |
| 50 | Lost in translation: returning germline genetic results in genome-scale cancer research. <i>Genome Medicine</i> , 2017, 9, 41.  | 8.2  | 27        |
| 51 | DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. <i>Communications Biology</i> , 2021, 4, 155.  | 4.4  | 26        |
| 52 | Returning individual research results for genome sequences of pancreatic cancer. <i>Genome Medicine</i> , 2014, 6, 42.  | 8.2  | 25        |
| 53 | Aniseikonia, metamorphopsia and perceived entoptic pattern: some effects of a macular epiretinal membrane, and the subsequent spontaneous separation of the membrane. <i>Ophthalmic and Physiological Optics</i> , 1995, 15, 339-343. | 2.0  | 23        |
| 54 | Real Time Intraoperative Confocal Laser Microscopy-Guided Surgery. <i>Annals of Surgery</i> , 2009, 249, 735-737.   | 4.2  | 22        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 55 | Personalising pancreas cancer treatment: When tissue is the issue. <i>World Journal of Gastroenterology</i> , 2014, 20, 7849.   | 3.3  | 22        |
| 56 | Retinoid Signaling in Pancreatic Cancer, Injury and Regeneration. <i>PLoS ONE</i> , 2011, 6, e29075.  | 2.5  | 20        |
| 57 | RON is not a prognostic marker for resectable pancreatic cancer. <i>BMC Cancer</i> , 2012, 12, 395.   | 2.6  | 17        |
| 58 | The epigenetic agents suberoylanilide hydroxamic acid and 5-AZA-2â€² deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo. <i>International Journal of Oncology</i> , 2015, 46, 2223-2230. | 3.3  | 17        |
| 59 | Defining the clinical genomic landscape for real-world precision oncology. <i>Genomics</i> , 2020, 112, 5324-5330.  | 2.9  | 16        |
| 60 | Asian gastric cancer patients show superior survival: the experiences of a single Australian center. <i>Gastric Cancer</i> , 2015, 18, 256-261.   | 5.3  | 15        |
| 61 | Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. <i>Human Genetics</i> , 2011, 130, 93-101.   | 3.8  | 13        |
| 62 | Pancreatic cancer genomics: where can the science take us?. <i>Clinical Genetics</i> , 2015, 88, 213-219.   | 2.0  | 13        |
| 63 | Role of endoscopic ultrasound in pancreatic cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 293-303.   | 3.0  | 12        |
| 64 | The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 683-695.  | 1.4  | 12        |
| 65 | Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice. <i>Annals of Oncology</i> , 2019, 30, 1691-1694.   | 1.2  | 12        |
| 66 | Muscle-Derived Cytokines Reduce Growth, Viability and Migratory Activity of Pancreatic Cancer Cells. <i>Cancers</i> , 2021, 13, 3820.   | 3.7  | 12        |
| 67 | An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer. <i>Molecular Oncology</i> , 2020, 14, 1800-1816.   | 4.6  | 10        |
| 68 | Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. <i>Nature Communications</i> , 2021, 12, 6738.   | 12.8 | 10        |
| 69 | Clinical and Molecular Risk Factors for Recurrence Following Radical Surgery of Well-Differentiated Pancreatic Neuroendocrine Tumors. <i>Frontiers in Medicine</i> , 2020, 7, 385.  | 2.6  | 7         |
| 70 | Individualizing therapy for pancreatic cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1779-1782.   | 2.8  | 6         |
| 71 | Taking optical biopsies with confocal endomicroscopy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1701-1703.  | 2.8  | 6         |
| 72 | Cancer Genetics and Implications for Clinical Management. <i>Surgical Clinics of North America</i> , 2015, 95, 919-934.   | 1.5  | 6         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 73 | ICGC-ARGO precision medicine: familial matters in pancreatic cancer. <i>Lancet Oncology</i> , The, 2022, 23, 25-26.  | 10.7 | 6         |
| 74 | Can we move towards personalised pancreatic cancer therapy?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 335-338.   | 3.0  | 5         |
| 75 | Role of PLEXIND1/TCF <sup>2</sup> Signaling Axis in Pancreatic Ductal Adenocarcinoma Progression Correlates with the Mutational Status of KRAS. <i>Cancers</i> , 2021, 13, 4048.   | 3.7  | 4         |
| 76 | Inherited Susceptibility to Pancreatic Cancer in the Era of Next-Generation Sequencing. <i>Gastroenterology</i> , 2015, 148, 496-498.  | 1.3  | 3         |
| 77 | Gastric cancer: Australian outcomes of multi-modality treatment with curative intent. <i>ANZ Journal of Surgery</i> , 2016, 86, 386-390.   | 0.7  | 3         |
| 78 | ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer. <i>Lancet Oncology</i> , The, 2022, 23, 463-464. | 10.7 | 3         |
| 79 | Spatial expression of IKK-alpha is associated with a differential mutational landscape and survival in primary colorectal cancer. <i>British Journal of Cancer</i> , 2022, , .     | 6.4  | 2         |
| 80 | Reply to G.F. Arroyo. <i>Journal of Clinical Oncology</i> , 2013, 31, 3843-3844.   | 1.6  | 0         |
| 81 | Stratified Medicine for Pancreatic Cancer. , 2014, , 807-814.  |      | 0         |
| 82 | Molecular Subtyping of Pancreatic Cancer. , 2021, , 305-319.   |      | 0         |